Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749919 | 0.91 | F10 (0.70) | F10 | |
| SCHEMBL3673841 | 0.90 | F10 (0.67) | F10 | |
| SCHEMBL2989816 | 0.88 | F10 (0.74) | F10 | |
| SCHEMBL78551 | 0.86 | F10 (0.82) | F10 | |
| SCHEMBL80172 | 0.86 | F10 (0.81) | F10 | |
| SCHEMBL3682223 | 0.85 | F10 (0.58) | F10 | |
| SCHEMBL5488439 | 0.82 | F10 (0.62) | F10 | |
| SCHEMBL78816 | 0.82 | F10 (1.00) | F10 | |
| SCHEMBL3679740 | 0.81 | F10 (0.71) | F10 | |
| SCHEMBL87195 | 0.79 | F10 (1.00) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| EP-2167499-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008155069-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155069-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, OXA1L, PPOX | F10 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.